First Engineered T Cell Receptor Trial Opens With New Cellular Therapy For HIV

Researchers at the University of Pennsylvania School of Medicine and Adaptimmune Limited today announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrollment of the first-ever study using patients’ cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR).

Source: First Engineered T Cell Receptor Trial Opens With New Cellular Therapy For HIV